1. Medtech Insight
  2. >>Business
  3. >>Deals

Financings In Brief

Tria Beauty postpones IPO. Agendia raises $65 million for cancer tests. Kona Medical gets $30 million for hypertension device development. More financings.

Aesthetic device maker TRIA Beauty Inc. postpones planned initial public offering May 23, citing unfavorable market conditions. The firm planned to raise up to $86.3 million, according to a preliminary IPO prospectus filed Jan. 30 with the Securities and Exchange Commission. (See Also see "Tria Preps 510(k) For OTC Skin Rejuvenating Laser, Files For IPO" - Medtech Insight, 6 February, 2012..) “The current volatility of the stock market and ongoing global economic instability do not provide an attractive environment for us to price this transaction at this time,” CEO Kevin Appelbaum said. However, the Dublin, Calif., firm notes that it has not withdrawn its IPO prospectus filing with SEC and expects to continue to evaluate the timing for the offering.

Maker of the MammaPrint in vitro diagnostic multivariate index assay for predicting breast cancer recurrence raises $65 million in a private round of equity financing led by Swiss drug development...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

 
• By Natasha Barrow

Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.

23andMe Purchase Will Let Regeneron Scale Drug Development

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Deals Shaping The Medtech And Diagnostics Industries, March 2025

 
• By Medtech Insight Team

An interactive look at medtech and diagnostics deals made during March 2025. Data courtesy of Biomedtracker.

Roar Of Eargo-hearX Merger Echoes Through US OTC Hearing Aid Market

 
• By Malcolm Spicer

The firms recently announced they will operate as combined company LXE Hearing marketing Eargo’s namesake line and hearX’s Lexie brands. Eargo majority owner Patient Square Capital added $100m to its investment.

More from Business

Bone Surgery Startup Surgify Medical Raises $7.9m

 
• By Natasha Barrow

Surgify Medical’s selective drill tip, Surgify Halo, is “an obvious choice for surgeons,” said Boris Hofmann, head of ZEISS Ventures and lead investor in the company’s series A funding round.

German Bionic Launches ‘Strongest Exoskeleton To Date’

 
• By Natasha Barrow

German Bionic’s new exoskeleton Exia helps healthcare practitioners, nurses, and other caregivers to lift and move patients by supporting muscle movement and reducing the risk of injury.

Medtronic Eyes Up to $350M Tariff Hit in FY26, Leans On Cost Controls And Pricing Strategy

 
• By Shubham Singh

Medtronic expects operating profit to grow approximately 7% in fiscal 2026, excluding tariff impacts. If tariffs materialize at the upper end of the projected range, operating profit growth could drop by 2.2 to 3.2 percentage points.